Related Experiment Video
Updated: Mar 28, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.5K
Factor-V HR2 haplotype and thromboembolic disease
Acta Cardiologica
|December 31, 2015
Summary
The factor V HR2 haplotype was more prevalent in pulmonary embolism patients than healthy individuals. However, this genetic factor was not found to be an independent risk factor for thrombosis after adjusting for other variables.
Area of Science:
- Genetics and Thrombosis Research
- Molecular Biology and Disease Risk
Background:
- The factor V gene HR2 haplotype has been investigated as a potential risk factor for venous thromboembolism (VTE).
- Previous studies on the association between HR2 haplotype and VTE have yielded conflicting results.
- Understanding the role of genetic polymorphisms in VTE is crucial for risk stratification.
Purpose of the Study:
- To determine the prevalence of the factor V HR2 polymorphism in patients diagnosed with pulmonary embolism (PE).
- To compare the HR2 haplotype frequency between PE patients and a control group of healthy subjects.
- To assess the association between the HR2 haplotype and the risk of developing thromboembolic events.
Main Methods:
- Genetic analysis was performed on 85 patients with PE and 72 healthy controls.
- Thrombophilia screening included genetic tests for factor V Leiden and the HR2 haplotype.
- Statistical analyses were conducted to compare frequencies and calculate odds ratios.
Main Results:
- The HR2 haplotype was found in 23.53% of PE patients and 8.3% of healthy controls, a statistically significant difference (P = 0.001).
- HR2 carriers showed a higher frequency of recurrent venous thrombosis or PE.
- Initial analysis indicated a three-fold increased risk of PE (OR = 3.38), but this association was not significant after adjusting for age and sex (OR = 1.22).
Conclusions:
- Despite a higher prevalence in PE patients, the factor V HR2 haplotype is not supported as an independent risk factor for thrombosis in this study.
- The association between HR2 and thromboembolic events appears to be confounded by factors such as age and sex.
- Further research may be needed to fully elucidate the role of the HR2 haplotype in thrombophilia.
More Related Videos
08:30Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
11.9K
06:59The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
85
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:29Venous Thrombosis III: Interprofessional Care
463
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
463
01:30Venous Thrombosis I: Introduction
677
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
677
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
434
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
434
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.2K